Collaborative Arrangements - Aggregate VIE Financial Information (Details) - USD ($)	3 Months Ended								12 Months Ended
	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Variable Interest Entity, Primary Beneficiary, Does Not Hold Majority Voting Interest, Disclosures [Abstract]
(Benefit from) provision for income taxes	$ (1,492,599,000)	$ 8,055,000	$ 10,341,000	$ (12,659,000)	$ 10,257,000	$ (125,903,000)	$ 4,337,000	$ 3,985,000	$ (1,486,862,000)	$ (107,324,000)	$ 16,665,000
Net loss (income) attributable to noncontrolling interest	25,431,000	$ 290,000	$ 1,110,000	(17,038,000)	(1,501,000)	188,315,000	$ (13,173,000)	$ (1,792,000)	9,793,000	171,849,000	(28,021,000)
Variable Interest Entity, Consolidated, Carrying Amount, Assets and Liabilities, Net:
Intangible assets	0				29,000,000				0	29,000,000
Deferred tax liabilities	0				6,341,000				0	6,341,000
Noncontrolling interest	0				13,727,000				0	13,727,000
Parion Sciences, Inc
Schedule of Collaborative Arrangement Agreements [Line Items]
Up-front payment									85,000,000			$ 85,000,000
Variable Interest Entity, Primary Beneficiary, Does Not Hold Majority Voting Interest, Disclosures [Abstract]
(Benefit from) provision for income taxes						(126,200,000)
(Increase) decrease in fair value of contingent payments						$ 69,600,000
BioAxone Biosciences, Inc
Schedule of Collaborative Arrangement Agreements [Line Items]
Up-front payment				$ 10,000,000					10,000,000				$ 10,000,000
Fair value of the contingent payments payable	0								0
Variable Interest Entity, Primary Beneficiary, Does Not Hold Majority Voting Interest, Disclosures [Abstract]
Contingent consideration liability	$ 18,900,000				18,900,000				18,900,000	18,900,000
Variable Interest Entity, Primary Beneficiary
Variable Interest Entity, Primary Beneficiary, Does Not Hold Majority Voting Interest, Disclosures [Abstract]
Loss attributable to noncontrolling interest before (benefit from) provision for income taxes and changes in fair value of contingent payments									31,191,000	223,379,000	10,086,000
(Benefit from) provision for income taxes									(3,668,000)	(114,090,000)	16,743,000
(Increase) decrease in fair value of contingent payments									(17,730,000)	62,560,000	(54,850,000)
Net loss (income) attributable to noncontrolling interest									9,793,000	171,849,000	(28,021,000)
Variable Interest Entity, Consolidated, Carrying Amount, Assets and Liabilities, Net:
Deferred tax liabilities					4,756,000					4,756,000
Noncontrolling interest					$ 13,727,000					13,727,000
Variable Interest Entity, Primary Beneficiary | Parion Sciences, Inc
Variable Interest Entity, Primary Beneficiary, Does Not Hold Majority Voting Interest, Disclosures [Abstract]
(Benefit from) provision for income taxes										14,800,000
(Increase) decrease in fair value of contingent payments									$ 0	63,460,000	(64,800,000)
Variable Interest Entity, Consolidated, Carrying Amount, Assets and Liabilities, Net:
Intangible assets											255,300,000
Variable Interest Entity, Primary Beneficiary | BioAxone Biosciences, Inc
Variable Interest Entity, Primary Beneficiary, Does Not Hold Majority Voting Interest, Disclosures [Abstract]
(Increase) decrease in fair value of contingent payments										$ (900,000)	$ 9,950,000